The Journal of Contemporary Dental Practice

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  25 (2024)
Volume  24 (2023)
Volume  23 (2022)
Volume  22 (2021)
Volume  21 (2020)
Volume  20 (2019)
Volume  19 (2018)
Volume  18 (2017)
Volume  17 (2016)
Volume  16 (2015)
Volume  15 (2014)
Volume  14 (2013)
Volume  13 (2012)
Volume  12 (2011)
Volume  11 (2010)
Volume  10 (2009)
Volume  9 (2008)
Volume  8 (2007)
Volume  7 (2006)
Volume  6 (2005)
Volume  5 (2004)
Volume  4 (2003)
Volume  3 (2002)
Volume  2 (2001)
Volume  1 (1999)
Related articles

VOLUME 16 , ISSUE 11 ( November, 2015 ) > List of Articles

RESEARCH ARTICLE

Antimicrobial Potential of Momordica charantia L. against Multiresistant Standard Species and Clinical Isolates

Rennaly de Freitas Lima, Edja Maria Melo de Brito Costa, José Hardman Sátiro de Lucena Filho, Ana Claudia Dantas de Medeiros, Jozinete Vieira Pereira, Ana Flávia Granville-Garcia

Citation Information : de Freitas Lima R, de Brito Costa EM, de Lucena Filho JH, de Medeiros AC, Pereira JV, Granville-Garcia AF. Antimicrobial Potential of Momordica charantia L. against Multiresistant Standard Species and Clinical Isolates. J Contemp Dent Pract 2015; 16 (11):854-858.

DOI: 10.5005/jp-journals-10024-1770

Published Online: 01-04-2016

Copyright Statement:  Copyright © 2015; The Author(s).


Abstract

Aim

The aim of the present study was to evaluate the antibacterial and antifungal potential in vitro of Momordica charantia L. against the microorganisms of clinical interest (standard strains and multiresistant isolates) in order to aggregate scientific information in relation to its use as a therapeutic product.

Materials and methods

M. charantia L. plant material was acquired in municipality of Malta, Paraiba, Brazil. The extract was obtained through maceration, filtration and then concentrated under reduced pressure in a rotary evaporator, resulting in a dough, and was then dried in an oven for 72 hours at 40°C. Antimicrobial action of ethanolic extract of seed M. charantia L. was evaluated based on the minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC) and minimum fungicidal concentration (MFC) against standard strains of bacteria, isolates multiresistant bacteria and Candida species, by microdilution in broth method.

Results

All organisms were sensitive to the extract, being considered strong antimicrobial activity (MIC and MBC/MFC < 0.125 mg/ml).

Conclusion

The M. charantia L. showed strong antimicrobial potential, with bactericidal and fungicidal profile, there is the prospect to constitute a new therapeutic strategy for the control of infections, particularly in multiresistant strains.

Clinical significance

The use of medicinal plants in treatment of infectious processes have an important function nowadays, due to the limitations of the use of synthetic antibiotics available, related specifically to the microbial resistance emergence.

How to cite this article

de Lucena Filho JHS, de Freitas Lima R, de Medeiros ACD, Pereira JV, Granville-Garcia AF, de Brito Costa EMM. Antimicrobial Potential of Momordica charantia L. against Multiresistant Standard Species and Clinical Isolates. J Contemp Dent Pract 2015;16(11):854-858.

PDF Share
  1. Treatment of oral candidiasis in patients with head and neck cancer: a systematic review. Revista da AMRIGS 2009;53(3):241-245.
  2. Complete genome sequence of pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 2000;406:959-964.
  3. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamaseproducing escherichia coli in nonhospitalized patients. J Clin Microbiol 2004;42(3):1089-1094.
  4. Methicillin-resistant Staphylococcus aureus: emerging community dissemination. An Bras Dermatol 2009;84(5):501-506.
  5. IMPs, VIMs and SPMs: the diversity of metallo-b-lactamases produced by carbapenem-resistant Pseudomonas aeruginosa in a Brazilian hospital. Clin Microbiol Infect 2005;11(1):73-76.
  6. Antimicrobial resistance of uropathogens among outpatients, 2000-2004. Rev Soc Bras Med Trop 2008;41(3):277-281.
  7. Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia. Antimicrob Chemother 2010;65:2658-2665.
  8. Improved efficacy of fluconazole against candidiasis using bio-based microemulsion technique. Biotechnol Appl Biochem 2013;60(4):417-429.
  9. Technological and biopharmaceutical optimization of nystatin release from a multiparticulate based bioadhesive drug delivery system. Eur J Pharmaceutical Sci 2013;49(2):258-264.
  10. Atividade antifúngica de antissépticos bucais sobre Candida spp. Revista Brasileira de Ciências da Saúde 2011;15(1):69-74.
  11. Novas formas comerciais de anfotericina B. Revista de Ciências Médicas (Campinas) 2005;14(2):187-197.
  12. A comparative study of risk factors and outcome among outpatient-acquired and nosocomial candidaemia. J Hospital Infec 2005;60(2):129-134.
  13. Risk factors and outcome for nosocomial breakthrough candidaemia. J Infect 2006;52:216-222.
  14. Antimicrobial activity of some promising plant oils, molecules and formulations. Ind J Exp Biol 2012;50(10):714-717.
  15. Antimicrobial activity of Schinus lentiscifolius (Anacardiaceae). J Ethnopharmacol 2013;148(2):486-491.
  16. Evaluation of some important chemical constituents of momordica charantia cultivated in hofuf. J Biological Sci 2004;4(5):628-630.
  17. Effect of ribosome-inactivating proteins on virus-infected cells. Inhibition of virus multiplication and of protein synthesis. Archives of Virology 1982;71:323-332.
  18. Pharmacological actions and potential uses of Momordica charantia: a review. J Ethnopharmacol 2004;93(1):123-132.
  19. Anti-diabetic properties and phytochemistry of Momordica charantia L. (Cucurbitaceae). Phytomedicine 1996;2:349-362.
  20. Chemical composition of momordica charantia L. fruits. J Agric Food Chem 1991;39(10):1762-1763.
  21. Abordagem Etnobotânica acerca do Uso de Plantas Medicinais na Vila Cachoeira, Ilhéus, Bahia, Brasil. Acta Farm. Bonaerense 2002;21(3):205-211.
  22. Hypoglycaemic effect of Momordica charantia extracts in normoglycaemic or cyproheptadine-induced hyperglycaemic mice. J Ethnopharmacol 1994;44(2):117-121.
  23. Effects of Momordica charantia L. on the blood rheological properties in diabetic patients. Bio Med Res Int 2014. Doi: 10.1155/2014/840379.
  24. Antiviral protein of Momordica charantia L. inhibits different subtypes of influenza A. Evidence-Based Complementary and Alternative Medicine 2013. Doi: 10.1155/2013/729081.
  25. Alpha-momorcharin inhibits HIV-1 replication in acutely but not chronically infected T-lymphocytes. Zhongguo Yao Li Xue Bao 1999;20(3):239-243.
  26. Antiproliferative and hypoglycemic cucurbitane- type glycosides from the fruits of Momordica charantia. J Agric Food Chem 2013;61(12):2979-2986.
  27. Wild bitter gourd protects against alcoholic fatty liver in mice by attenuating oxidative stress and inflammatory responses. Food Funct 2014;5(5):1027-1037.
  28. Trypanocide, cytotoxic, and antifungal activities of Momordica charantia. Pharm Biol 2012;50(2): 162-166.
  29. Antimicrobial, antioxidant activities and total phenolic content of Thai medicinal plants used to treat HIV patients. J Med Assoc Thai 2012;95(Suppl 1):S154-158.
  30. Antiulcer activity of methanolic extract of Momordica charantia L. in rats. J Ethnopharmacol 2009;123(3):464-469.
  31. 28, no. 14, CLSI document M27-A3, Wayne, PA, USA, 3rd ed. 2008.
  32. vol 29, no 2, CLSI document M07-A8, Wayne, PA, USA, 2009.
  33. Composition and antimicrobial activity of essencial oil of two Origanum species. J Agricul Food Chemis 2001;40:4168-4170.
  34. Dissemination in distinct Brazilian regions of na epidemic carbapenemresistant Pseudomonas aeruginosa producing SPM metallo- β-lactamases. J Antimicrob Chemoter 2003;52:699-702.
  35. Reduced susceptibility of proteus mirabilis to triclosan. Antimicrobial Agents and Chemotherapy 2008;52(3):991-994.
  36. Extended-spectrum beta-lactamases among Enterobacteriaceae isolated in a public hospital in Brazil. Rev Inst Med trop 2009;51(4):203-209.
  37. Prevalencia de candidose bucal em pacientes hospitalizados e avaliacao dos fatores de risco Revista Sul-Brasileira de Odontologia (Online) 2010;7(1):66-72.
  38. Fungal infections of the oral mucosa. Ind J Dent Res 2012;23(5):650-659.
  39. In vitro evaluation of phospholipase and proteinase of Candida albicans isolated from oral cavity of diabetic patients. UNOPAR Cientifica Ciencias Biologicas e da Saude 2013;15(1):9-12.
  40. Candida colonisation in asymptomatic HIV patients attending a tertiary hospital in Benin City, Nigeria. Libyan J Med 2013;18(8):1-5.
  41. Unilateral presentation of disseminated candidiasis: case report and review of the literature. Cutis 2013;91(3):137-140.
  42. Antimicrobial activity of some medicinal plants extracts on Escherichia coli, Salmonella paratyphi and Shigella dysenteriae. Afr J Med Sci 1996;25:373-375.
  43. Screening of Turkish antiulcerogenic folk remedies for anti-Helicobacter pylori activity. J Ethnopharmacol 1999;66:289-293.
  44. Determination of minimum inhibitory concentrations. J Antimicrob Chemother 2001;48(1):5-16.
  45. Estudo comparativo de tecnicas de screening para avaliacao da atividade antibacteriana de extratos brutos de especies vegetais e de substancias puras. Quim Nova 2008;31(5):1224-1229.
  46. Plantas Medicinais: fatores de influencia no conteudo de metabolitos secundarios. Quim Nova 2007;30(2):374-381.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.